Child
FDA Approves Revolutionary Re-Expandable Stent for Young Children
FDA approval, re-expandable stent, young children, congenital heart disease, minimally invasive procedures
BioMarin’s Brineura Receives Significant Label Expansion from FDA for Children Under 3 with CLN2 Disease
BioMarin, Brineura, FDA, Label Expansion, CLN2 Disease, Children Under 3, Cerliponase Alfa, Intraventricular Injection, Motor Ability Deterioration, Neurodegenerative Symptoms
Pioneering Gene Therapy Restores Hearing in Children with Otoferlin-Linked Deafness
Gene therapy, otoferlin-related deafness, hearing restoration, children, genetic mutation, clinical trial, auditory function.
FDA Fast-Tracks Day One’s Innovative Therapy for Pediatric Brain Tumors
FDA, accelerated approval, Day One, targeted treatment, pediatric brain tumors, glioma, children, cancer treatment, innovative therapy.
AstraZeneca’s FASENRA Gains FDA Approval for Add-On Maintenance Treatment of Severe Asthma in Children Aged 6-11
AstraZeneca, FASENRA, Benralizumab, Severe Asthma, Pediatric Label Expansion, FDA Approval, Children Aged 6-11
Sarepta’s ELEVIDYS Gaining Ground Amidst Anticipation for Expanded Label Approval
ELEVIDYS, Age, Muscular Dystrophy, Duchenne, Sarepta, Labels (device), Child
New York Attorney General Demands Enhanced Safety Labeling for Pediatric Use of Singulair
Singulair, United States Food and Drug Administration, Pediatric brand name, Child, Lawyer (occupation)
Shanghai startup’s gene therapy restores hearing in five deaf children, running ahead of Lilly and Regeneron trials
Child, Hearing, Hearing Impaired Persons, gene therapy
Sanofi, Regeneron Win Dupixent Label Expansion to Treat Eosinophilic Esophagitis
Eosinophilic esophagitis, Dupixent, Child, Treatment intent, sanofi, Regeneron
Forta Healthcare: $55M Series A to Scale AI-Driven Parent-Led Autism Therapy and Expand Services
Forta, Child, Applied Behavior Analysis